Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
- CAS Registry Number
- 914088-09-8
- FDA UNII
- 7XL5ISS668
- Approximate molecular weight
- Approximately 153 kDa
- Drug class
- CD30-directed antibody–drug conjugate (brentuximab vedotin)
- Mechanism of action
- Brentuximab vedotin binds CD30 on target cells and is internalised. Lysosomal proteolysis releases monomethyl auristatin E (MMAE), which binds tubulin, disrupts microtubules, induces cell-cycle arrest and promotes apoptosis.
- Indications / reported uses
- EMA-authorised indications include selected CD30-positive Hodgkin lymphoma, systemic anaplastic large-cell lymphoma and cutaneous T-cell lymphoma settings; consult current product information for exact lines and combinations
Identification sources: The FDA ADCETRIS prescribing information reports an approximate molecular weight of 153 kDa and approximately four MMAE molecules per antibody. Because the drug-to-antibody ratio varies, the conjugate has no single exact molecular formula or molecular weight.